Read news from:
Austria
SHARE
COPY LINK

HEALTH

Epilepsy drug caused thousands of severe birth defects in France

The epilepsy medication valproate is responsible for "severe malformations" in 2,150 to 4,100 children in France since the drug was first marketed in the country in 1967, according to a preliminary study by French health authorities.

Published: 20 April 2017 12:31 CEST
Epilepsy drug caused thousands of severe birth defects in France
File photo: AFP
Women who took the drug during pregnancy to treat epilepsy were four times more likely to give birth to babies with congenital malformations, said the report, jointly issued by the French National Agency for the Safety of Medicines (ANSM) and the national health insurance administration.
   
“The study confirms the highly teratogenic” — that is, capable of causing birth defects — “nature of valproate,” Mahmoud Zureik, scientific director of ANSM and co-author of the report, told AFP ahead of its release.
 
“The figure of about 3,000 severe malformations is very high,” he told AFP in an interview before the findings were made public.
 
The types of birth defects attributed to the drug included spina bifida — a condition in which the spinal cord does not form properly, and can protrude through the skin — as well as defects of the heart and genital organs.
 
The risk of autism and developmental problems was also found to be higher, and will be quantified in a follow-up report due later this year.
 
An earlier estimate suggested that 30 to 40 percent of children exposed in the womb could suffer such disorders.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

HEALTH

Lengthy waiting times at Danish hospitals not going away yet: minister

Danish Minister for the Interior and Health Sophie Løhde has warned that, despite increasing activity at hospitals, it will be some time before current waiting lists are reduced.

Published: 10 May 2023 15:09 CEST
Lengthy waiting times at Danish hospitals not going away yet: minister

The message comes as Løhde was set to meet with officials from regional health authorities on Wednesday to discuss the progress of an acute plan for the Danish health system, launched at the end of last year in an effort to reduce a backlog of waiting times which built up during the coronavirus crisis.

An agreement with regional health authorities on an “acute” spending plan to address the most serious challenges faced by the health services agreed in February, providing 2 billion kroner by the end of 2024.

READ ALSO: What exactly is wrong with the Danish health system?

The national organisation for the health authorities, Danske Regioner, said to newspaper Jyllands-Posten earlier this week that progress on clearing the waiting lists was ahead of schedule.

Some 245,300 operations were completed in the first quarter of this year, 10 percent more than in the same period in 2022 and over the agreed number.

Løhde said that the figures show measures from the acute plan are “beginning to work”.

“It’s positive but even though it suggests that the trend is going the right way, we’re far from our goal and it’s important to keep it up so that we get there,” she said.

“I certainly won’t be satisfied until waiting times are brought down,” she said.

“As long as we are in the process of doing postponed operations, we will unfortunately continue to see a further increase [in waiting times],” Løhde said.

“That’s why it’s crucial that we retain a high activity this year and in 2024,” she added.

Although the government set aside 2 billion kroner in total for the plan, the regional authorities expect the portion of that to be spent in 2023 to run out by the end of the summer. They have therefore asked for some of the 2024 spending to be brought forward.

Løhde is so far reluctant to meet that request according to Jyllands-Posten.

SHOW COMMENTS